Cannabis Report
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Hayward .. i did similar you will be

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ranjo Member Profile
 
Followed By 1
Posts 258
Boards Moderated 0
Alias Born 05/28/11
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/24/2018 4:42:59 PM
Amarin Announces Patent Litigation Settlement Agreement with Teva GlobeNewswire Inc. - 5/24/2018 4:35:12 PM
Amarin to Present at the Jefferies Global Healthcare Conference GlobeNewswire Inc. - 5/23/2018 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/18/2018 5:02:34 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/2/2018 6:36:02 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/2/2018 6:31:04 AM
Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 5/2/2018 5:00:00 AM
Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018 GlobeNewswire Inc. - 4/26/2018 5:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2018 8:01:41 AM
Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer GlobeNewswire Inc. - 4/23/2018 5:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/20/2018 8:02:28 AM
Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions GlobeNewswire Inc. - 4/12/2018 4:30:00 PM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Pat... GlobeNewswire Inc. - 4/12/2018 5:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 4/5/2018 4:23:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/4/2018 4:17:54 PM
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes... GlobeNewswire Inc. - 4/4/2018 5:15:00 AM
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Card... GlobeNewswire Inc. - 4/4/2018 5:00:00 AM
Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings GlobeNewswire Inc. - 3/29/2018 5:00:00 AM
Amarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire Inc. - 3/28/2018 4:30:00 PM
Amarin Commemorates National Triglycerides Day on March 28 GlobeNewswire Inc. - 3/27/2018 4:30:00 PM
Amarin Announces First Middle East Approval for Vascepa® GlobeNewswire Inc. - 3/21/2018 5:00:00 AM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Per... GlobeNewswire Inc. - 3/12/2018 4:30:00 PM
Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare ... GlobeNewswire Inc. - 3/12/2018 4:30:00 PM
Amarin Announces Closing of Underwriter’s Purchase of Additional Shares GlobeNewswire Inc. - 3/5/2018 4:35:32 PM
Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study GlobeNewswire Inc. - 3/1/2018 5:00:00 AM
ranjo   Friday, 02/09/18 05:39:27 PM
Re: hayward post# 122388
Post # of 128961 
Hayward .. i did similar you will be greatly rewarded .. don't beat yourself up over not catching the low i try to focus on 20+

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist